Highest Quality Supplements Since 1980

Hepatitis C References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. NIH (National Institutes of Health - National Institute of Allergy and Infectious Diseases). "Hepatitis C." Available at:
    http://www.niaid.nih.gov/topics/hepatitis/hepatitisc/Pages/Default.aspx. Last updated October 1, 2009. Accessed April 26, 2012.
  2. Rosen HR. Clinical Practice. Chronic Hepatitis C Infection. N Engl J Med 2011; 364:2429-2438 June 23, 2011
  3. Holmberg S. "The Growing Burden of Mortality Associated with Viral Hepatitis in the United States, 1999-2007." The Liver Meeting 2011: American Association for the Study of Liver Diseases (AASLD) 62nd Annual Meeting. Abstract 243. Presented November 8, 2011.
  4. Rubin A, Aguilera V, and Berenguer M. Liver transplantation and hepatitis C. Clin Res Hepatol Gastroenterol. 2011 Dec;35(12):805-12. Epub 2011 Oct 1.
  5. Chen SL, Morgan TR. "The Natural History of Hepatitis C Virus (HCV) Infection." Int J Med Sci 3.2 (2006): 47-52. http://www.medsci.org/v03p0047.htm
  6. Mayo Clinic. Hepatitis C. Updated 5/24/2011. Available at:
    http://www.mayoclinic.com/health/hepatitis-c/DS00097 Accessed: 5/29/2012.
  7. McDonald J, Burroughs A, Feagan B, eds. Evidence-Based Gastroenterology &Hepatology. Hoboken, NJ: Wiley-Blackwell; 2010. http://bit.ly/z3ue7W
  8. Poo JL, Sánchez Avila F, Kershenobich D, et al. "Efficacy of Triple Therapy with Thymalfasin, Peginterferon alpha-2a, and Ribavirin for the Treatment of Hispanic Chronic HCV Nonresponders." Ann Hepatol 7.4 (2008): 369-75. http://www.medigraphic.com/pdfs/hepato/ah-2008/ah084j.pdf
  9. Baek YH, Lee SW, Yoo HS, et al. "Thymosin Alpha-1 in Combination with Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients Who have Failed to Prior Pegylated Interferon and Ribavirin Treatment." Gut Liver 1.1 (2007): 87-9. http://www.ncbi.nlm.nih.gov/pubmed/20485665
  10. Ciancio A, Rizzetto M. "Thymalfasin in the Treatment of Hepatitis B and C." Ann N Y AcadSci 1194 (2010): 141-6. http://www.ncbi.nlm.nih.gov/pubmed/20536462
  11. Yu JW, Sun LJ, Zhao YH. "The Effect of Metformin on the Efficacy of Antiviral Therapy in Patients with Genotype 1 Chronic Hepatitis C and Insulin Resistance." Int J Infect Dis 2012. [Epub ahead of print]
  12. Romero-Gómez M, Diago M, Andrade RJ, et al. "Treatment Of Insulin Resistance With Metformin In Naïve Genotype 1 Chronic Hepatitis C Patients Receiving Peginterferon Alfa-2a Plus Ribavirin." Hepatology 50.6 (2009): 1702-8. http://www.ncbi.nlm.nih.gov/pubmed/19845037
  13. Nkontchou G, Cosson E, Aout M, et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J ClinEndocrinolMetab. 2011 Aug;96(8):2601-8.
  14. World Health Organization, Global Alert and Response. "Hepatitis C." Available at:
    http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index1.html. Accessed March 9, 2012.
  15. Williams IT, Bell BP, Kuhnert W, Alter MJ. "Incidence and Transmission Patterns of Acute Hepatitis C in the United States, 1982-2006." Arch Intern Med 171.3 (2011): 242-8.
  16. U.S. Centers for Disease Control and Prevention (CDC). "Hepatitis C FAQs for the Public." Available at:
    http://www.cdc.gov/hepatitis/C/cFAQ.htm. Last updated April 26, 2012a. Accessed March 9, 2012.
  17. Cavalheiro, Nde P. "Sexual Transmission of Hepatitis C." Rev Inst Med Trop Sao Paulo 49.5 (2007): 271-7. http://www.ncbi.nlm.nih.gov/pubmed/18026632
  18. Vandelli C, Renzo F, Romanò L, et al. "Lack of Evidence of Sexual Transmission of Hepatitis C among Monogamous Couples: Results of a 10-Year Prospective Follow-Up Study." Am J Gastroenterol 99.5 (2004): 855-9. http://www.ncbi.nlm.nih.gov/pubmed/15128350
  19. Fierer DS, Uriel AJ, Carriero DC, et al. "Liver Fibrosis during an Outbreak of Acute Hepatitis C Virus Infection in HIV-Infected Men: A Prospective Cohort Study." J Infect Dis 198.5 (2008): 683-6.
  20. Schmidt AJ, Rockstroh JK, Vogel M, et al. "Trouble with Bleeding: Risk Factors for Acute Hepatitis C among HIV-Positive Gay Men from Germany--A Case-Control Study." PLoS One 6.3 (2011): e17781.
  21. U.S. Centers for Disease Control and Prevention (CDC). "Hepatitis C FAQs for Health Professionals." Available at:
    http://www.cdc.gov/hepatitis/HCV/HCVfaq.htm. Last updated August 4, 2011. Accessed March 9, 2012.
  22. Chakravarty D, Lee WC, Chen YC, Jan YY, Lee P. Liver Transplantation. New Delhi, India: Jaypee Brothers Medical Publishers; 2010. http://bit.ly/Ag4Un5
  23. Dooley JS, Lok AS, Burroughs AK, Heathcote EJ, eds. Sherlock's Diseases of the Liver and Biliary System. 12th ed. Hoboken, NJ: Wiley-Blackwell; 2011.
  24. NIH-NDDIC. National Digestive Diseases Information Clearinghouse; National Institutes of Health. Updated 5/10/2012. Available at:
    http://digestive.niddk.nih.gov/ddiseases/pubs/hepc_ez/#6 Accessed: 5/29/2012.
  25. Cheifetz AS, Brown A, Curry M, Moss AC. Oxford American Handbook of Gastroenterology and Hepatology. New York: Oxford University Press; 2011. http://bit.ly/y8zpDB
  26. Hepatitis C Technical Advisory Group. United States Department of Veterans Affairs. Hepatitis C and Hepatocellular Carcinoma. Updated 6/21/2005. Available at:
    http://www.hepatitis.va.gov/provider/reviews/HCC.asp Accessed 5/30/2012.
  27. Angelico M. Epidemiology and outcome of hepatitis C relapse in transplant recipients. Transplant Proc. 2011 Jul-Aug;43(6):2457-8.
  28. Gordon FD, Kwo P, Vargas HE. Treatment of hepatitis C in liver transplant recipients. Liver Transpl. 2009 Feb;15(2):126-35.
  29. Narang TK, Ahrens W, and Russo MW. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl. 2010 Nov;16(11):1228-35.
  30. Fujita N, Sugimoto R, Takeo M, et al. "Hepcidin Expression in the Liver: Relatively Low Level in Patients with Chronic Hepatitis C." Mol Med 13.1-2 (2007): 97-104.
  31. Miura K, Taura K, Kodama Y, et al. "Hepatitis C Virus-Induced Oxidative Stress Suppresses Hepcidin Expression through Increased Histone Deacetylase Activity." Hepatology 48.5 (2008): 1420-9.
  32. Nishina S, Hino K, Korenaga M, et al. "Hepatitis C Virus-Induced Reactive Oxygen Species Raise Hepatic Iron Level in Mice by Reducing Hepcidin Transcription." Gastroenterology 134.1 (2008):226-38.
  33. De Domenico I, Ward DM, Kaplan J. "Hepcidin Regulation: Ironing Out the Details." J Clin Invest 117.7 (2007): 1755-8.
  34. Girelli D, Pasino M, Goodnough JB, et al. "Reduced Serum Hepcidin Levels in Patients with Chronic Hepatitis C." J Hepatol 51.5 (2009): 845-52. http://www.ncbi.nlm.nih.gov/pubmed/19729219
  35. Tsochatzis E, Papatheodoridis GV, Koliaraki V, et al. "Serum Hepcidin Levels Are Related to the Severity of Liver Histological Lesions in Chronic Hepatitis C." J Viral Hepat 17.11 (2010): 800-6.
  36. Fujinaga H, Tsutsumi T, Yotsuyanagi H, et al. "Hepatocarcinogenesis in Hepatitis C: HCV Shrewdly Exacerbates Oxidative Stress by Modulating Both Production and Scavenging of Reactive Oxygen Species." Oncology 81 Suppl 1 (2011): 11-7. http://www.ncbi.nlm.nih.gov/pubmed/22212930
  37. Price L, Kowdley KV. "The Role of Iron in the Pathophysiology and Treatment of Chronic Hepatitis C." Can J Gastroenterol 23.12 (2009): 822-8. http://www.ncbi.nlm.nih.gov/pubmed/20011735
  38. Fujita N, Sugimoto R, Ma N, et al. "Comparison of Hepatic Oxidative DNA Damage in Patients with Chronic Hepatitis B and C." J Viral Hepat 15.7 (2008): 498-507.
  39. Moriya K, Miyoshi H, Shinzawa S, et al. "Hepatitis C Virus Core Protein Compromises Iron-Induced Activation of Antioxidants in Mice and Hepg2 Cells." J Med Virol 82.5 (2010): 776-92.
  40. Sumida Y, Kanemasa K, Fukumoto K, et al. "Effects of Dietary Iron Reduction versus Phlebotomy in Patients with Chronic Hepatitis C: Results from a Randomized, Controlled Trial on 40 Japanese Patients." Intern Med 46.10 (2007): 637-42. http://www.ncbi.nlm.nih.gov/pubmed/17527035
  41. Sartori M, Andorno S, Rossini A, et al. "A Case-Control Histological Study on the Effects of Phlebotomy in Patients with Chronic Hepatitis C." Eur J GastroenterolHepatol 23.12 (2011): 1178-84.
  42. Di Bisceglie AM, Bonkovsky HL, Chopra S, et al. "Iron Reduction As An Adjuvant To Interferon Therapy In Patients With Chronic Hepatitis C Who Have Previously Not Responded To Interferon: A Multicenter, Prospective, Randomized, Controlled Trial." Hepatology 32.1 (2000): 135-8.
  43. Alexander J, Tung BY, Croghan A, et al. "Effect of Iron Depletion on Serum Markers of Fibrogenesis, Oxidative Stress and Serum Liver Enzymes in Chronic Hepatitis C: Results of a Pilot Study." Liver Int 27.2 (2007): 268-73. http://www.ncbi.nlm.nih.gov/pubmed/17311623
  44. Desai TK, Jamil LH, Balasubramaniam M, et al. "Phlebotomy Improves Therapeutic Response to Interferon in Patients with Chronic Hepatitis C: A Meta-Analysis of Six Prospective Randomized Controlled Trials." Dig Dis Sci 53.3 (2008): 815-22. http://www.ncbi.nlm.nih.gov/pubmed/17846887
  45. Kato J, Miyanishi K, Kobune M, et al. "Long-Term Phlebotomy with Low-Iron Diet Therapy Lowers Risk of Development of Hepatocellular Carcinoma from Chronic Hepatitis C." J Gastroenterol 42.10 (2007): 830-6. http://www.ncbi.nlm.nih.gov/pubmed/17940836
  46. Wilkins T, Malcolm JK, Raina D, et al. “Hepatitis C: Diagnosis and Treatment.” Am Fam Physician. 2010 Jun 1;81(11):1351-7. http://www.aafp.org/afp/2010/0601/p1351.html
  47. U.S. Centers for Disease Control and Prevention (CDC). “CDC Announces First Ever National Hepatitis Testing Day and Proposes that All Baby Boomers Be Tested Once for Hepatitis C.”May 18, 2012c. Available at:
    http://www.cdc.gov/nchhstp/Newsroom/HepTestingRecsPressRelease2012.html Accessed 5/30/2012.
  48. Boursier J, de Ledinghen V, Zarski JP, et al. "A New Combination of Blood Test and Fibroscan for Accurate Non-Invasive Diagnosis of Liver Fibrosis Stages in Chronic Hepatitis C." Am J Gastroenterol 106.7 (2011): 1255-63. http://www.ncbi.nlm.nih.gov/pubmed/21468012
  49. Echosens. FibroScan® 502 Touch. Available at:
    http://www.echosens.com/Products/fibroscanr-502-touch.html Accessed 5/31/2012.
  50. Cales P. Presentation; Angers University, France. Non-invasive evaluation of liver fibrosis: current clinical use and next perspectives (chronic hepatitis C). 3/21/2011. Available at: http://crm.therapyedge.com/wp-content/uploads/2011/08/fm_easl.pdf Accessed 5/31/2012.
  51. Cales P, Boursier J, Oberti F, et al. FibroMeters: a family of blood tests for liver fibrosis. GastroenterolClin Biol. 2008 Sep;32(6 Suppl 1):40-51.
  52. Boursier J, de Ledinghen V, Zarski JP, et al. "Comparison Of Eight Diagnostic Algorithms for Liver Fibrosis in Hepatitis C: New Algorithms Are More Precise And Entirely Noninvasive." Hepatology 55.1 (2012): 58-67.
  53. Poynard T, Ngo Y, Perazzo H, et al. Prognostic value of liver fibrosis biomarkers: a meta-analysis. GastroenterolHepatol (N Y). 2011 Jul;7(7):445-54.
  54. Vergniol J, Foucher J, Terrebonne E, et al. "Noninvasive Tests for Fibrosis and Liver Stiffness Predict 5-Year Outcomes of Patients with Chronic Hepatitis C." Gastroenterology 140.7 (2011): 1970-9, 1979.e1-3.
  55. Poynard T. Fibrosure (Fibrotest–ActiTest) – Towards a Universal Biomarker of Liver Fibrosis. Available at:
    http://www.touchbriefings.com/pdf/1043/LabCorp_tech.pdf Accessed. 5/31/2012.
  56. Fort GG and Mikolich DJ. Ferri: Ferri's Clinical Advisor 2012, 1st ed. Available at:
    http://www.mdconsult.com/books/page.do?eid=4-u1.0-B978-0-323-05611-3..00017-3--sc0095&isbn=978-0-323-05611-3&uniqId=337149870-3#4-u1.0-B978-0-323-05611-3..00017-3--sc0095 Accessed 5/30/2012.
  57. Munir S, Saleem S, Idrees M, et al. Hepatitis C treatment: current and future perspectives. Virol J. 2010 Nov 1;7:296.
  58. Alkhouri N, ZeinNN."Protease Inhibitors: Silver Bullets for Chronic Hepatitis C Infection?" Cleve Clin J Med 79.3 (2012): 213-22. http://www.ncbi.nlm.nih.gov/pubmed/22383557
  59. Russmann S, Grattagliano I, Portincasa P, et al. "Ribavirin-Induced Anemia: Mechanisms, Risk Factors and Related Targets for Future Research." Curr Med Chem 13.27 (2006): 3351-7.
  60. Hino K, Murakami Y, Nagai A, et al. “Alpha-Tocopherol [Corrected] and Ascorbic Acid Attenuates the Ribavirin [Corrected] Induced Decrease of Eicosapentaenoic Acid in Erythrocyte Membraine in Chronic Hepatitis C Patients.” J Gastroenterol Hepatol. 21.8 (2006):1269-75.
  61. Krishnan SM, Dixit NM. "Ribavirin-Induced Anemia in Hepatitis C Virus Patients Undergoing Combination Therapy." PLoSComput Biol. 7.2 (2011): e1001072.
  62. Reddy KR, Shiffman ML, Morgan TR, et al. "Impact of Ribavirin Dose Reductions in Hepatitis C Virus Genotype 1 Patients Completing Peginterferon Alfa-2a/Ribavirin Treatment." ClinGastroenterolHepatol 5.1 (2007): 124-9. http://www.ncbi.nlm.nih.gov/pubmed/17196435
  63. Thevenot T, Di Martino V, Lunel-Fabiani F, et al. "[Complementary Treatments of Chronic Viral Hepatitis C]." GastroenterolClinBiol 30.2 (2006): 197-214.
  64. Morisco F, Vitaglione P, Carbone A, et al. "Tomato-Based Functional Food as Interferon Adjuvant in HCV Eradication Therapy." J ClinGastroenterol 38.6 Suppl (2004): S118-20.
  65. Kawaguchi Y, Mizuta T, Takahashi K, et al. "High-Dose Vitamins E and C Supplementation Prevents Ribavirin-Induced Hemolytic Anemia in Patients with Chronic Hepatitis C." Hepatol Res 37.5 (2007): 317-24. http://www.ncbi.nlm.nih.gov/pubmed/17441803
  66. Hino K, Murakami Y, Nagai A, et al. "Alpha-Tocopherol [Corrected] and Ascorbic Acid Attenuates the Ribavirin [Corrected] Induced Decrease of Eicosapentaenoic Acid in Erythrocyte Membrane in Chronic Hepatitis C Patients." J Gastroenterol Hepatol 21.8 (2006): 1269-75.
  67. Zeuzem S, Andreone P, Pol S, et al. "Telaprevir for Retreatment of HCV Infection." N Engl J Med 364.25 (2011): 2417-28. http://www.ncbi.nlm.nih.gov/pubmed/21696308
  68. Kim JJ, Culley CM, Mohammad RA. "Telaprevir: An Oral Protease Inhibitor for Hepatitis C Virus Infection." Am J Health Syst Pharm 69.1 (2012): 19-33. http://www.ncbi.nlm.nih.gov/pubmed/22180548
  69. Feret B. "Boceprevir: A New Oral Protease Inhibitor for the Treatment of Chronic Hepatitis C." Formulary 46 (2011): 352-366.
  70. Jacobson IM, McHutchison JG, Dusheiko G, et al. "Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection." N Engl J Med 364.25 (2011): 2405-16.
  71. U.S. Centers for Disease Control and Prevention (CDC). " Hepatitis C in the African American Community " Available at:
    http://www.cdc.gov/hepatitis/Populations/AAC-HepC.htm. Last updated March 1, 2012b. Accessed March 9, 2012.
  72. American College of Gastroenterology. "New Research on Improved Treatment Options and Screening Strategies for Hepatitis C." Available at:
    http://d2j7fjepcxuj0a.cloudfront.net/wp-content/uploads/2011/10/2011-ACG-Hepatitis-C-FINAL.pdf. October 31, 2011. Accessed March 9, 2012.
  73. Sherman KE, Flamm SL, Afdhal NH, et al. "Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection." N Engl J Med 365.11 (2011): 1014-24.
  74. Lo Re V 3rd, Teal V, Localio AR., et al. "Relationship between Adherence to Hepatitis C Virus Therapy and Virologic Outcomes: A Cohort Study." Ann Intern Med 155.6 (2011): 353-60.
  75. Poordad F, McCone J Jr, Bacon BR, et al. "Boceprevir for Untreated Chronic HCV Genotype 1 Infection." N Engl J Med 364.13 (2011): 1195-206.
  76. Kwo PY, Lawitz EJ, McCone J, et al. "Efficacy of Boceprevir, an NS3 Protease Inhibitor, in Combination with Peginterferon Alfa-2b and Ribavirin in Treatment-Naive Patients with Genotype 1 Hepatitis C Infection (SPRINT-1): An Open-Label, Randomised, Multicentre Phase 2 Trial." Lancet 376.9742 (2010): 705-16.
  77. Ghany MG, Nelson DR, Strader DB, et al. "An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases." Hepatology 54.4 (2011): 1433-44. http://www.ncbi.nlm.nih.gov/pubmed/21898493
  78. Sarrazin C, Zeuzem S. "Resistance to Direct Antiviral Agents in Patients with Hepatitis C Virus Infection." Gastroenterology 138.2 (2010): 447-62. http://www.ncbi.nlm.nih.gov/pubmed/20006612
  79. Susser S, Welsch C, Wang Y, et al. "Characterization of Resistance to the Protease Inhibitor Boceprevir in Hepatitis C Virus-Infected Patients." Hepatology 50.6 (2009): 1709-18.
  80. Kuntzen T, Timm J, Berical A, et al. "Naturally Occurring Dominant Resistance Mutations to Hepatitis C Virus Protease and Polymerase Inhibitors in Treatment-Naïve Patients." Hepatology 48.6 (2008): 1769-78. http://www.ncbi.nlm.nih.gov/pubmed/19026009
  81. Shiffman ML, ed. Chronic Hepatitis C Virus: Advances in Treatment, Promise for the Future. New York: Springer Science+Business Media, LLC; 2012.
  82. Nakashima K, Takeuchi K, Chihara K, et al. "Inhibition of Hepatitis C Virus Replication through Adenosine Monophosphate-Activated Protein Kinase-Dependent and -Independent Pathways." MicrobiolImmunol. 55.11 (2011): 774-82. http://www.ncbi.nlm.nih.gov/pubmed/21895746
  83. del Campo JA, López RA, Romero-Gómez M. "Insulin Resistance and Response to Antiviral Therapy in Chronic Hepatitis C: Mechanisms and Management." Dig Dis 28.1 (2010): 285-93.
  84. Sainz B Jr, Barretto N, Martin DN, et al. "Identification of the Niemann-Pick C1-Like 1 Cholesterol Absorption Receptor as a New Hepatitis C Virus Entry Factor." Nat Med 18.2 (2012): 281-5.
  85. Zeuzem S, et al. "SVR4 and SVR12 with an Interferon-Free Regimen of BI 201335 and BI 207127 +/- Ribavirin, in Treatment-Naive Patients with Chronic Genotype-1 HCV Infection." Abstract#101 presented at the International Liver CongressTM (ILC), 18 -22 April 2012. Summary available at: http://www.natap.org/2012/EASL/EASL_19.htm
  86. Hanlon J. University of Alberta. "Vaccine Discovered for Hep C." Available at:
    http://www.news.ualberta.ca/article.aspx?id=B04932D68EF6488A8DE62A463FFA7487. February 15, 2012. Accessed March 7, 2012.
  87. Sherman KE. "Thymosin Alpha 1 for Treatment of Hepatitis C Virus: Promise and Proof." Ann N Y AcadSci 1194 (2010): 136-40.
  88. Ciancio A, Andreone P, Kaiser S, et al. Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role? J Viral Hepat. 2012 Jan;19 Suppl 1:52-9. doi: 10.1111/j.1365-2893.2011.01524.x.
  89. Cacciatore I, Cornacchia C, Pinnen F, et al. “Prodrug Approach for Increasing Cellular Glutathione Levels.” Molecules 15.3 (2010): 1242-64.
  90. Tapryal N, Mukhopadhyay C, Mishra MK, et al. "Glutathione Synthesis Inhibitor ButathioneSulfoximine Regulates Ceruloplasmin by Dual but Opposite Mechanism: Implication in Hepatic Iron Overload." Free RadicBiol Med 48.11 (2010): 1492-500.
  91. Nguyen-Khac E, Thevenot T, Piquet MA, et al. "Glucocorticoids Plus N-Acetylcysteine in Severe Alcoholic Hepatitis." N Engl J Med 365.19 (2011): 1781-9.
  92. Kortsalioudaki C, Taylor RM, Cheeseman P, et al. “Safety and Efficacy of N-Acetylcysteine in Children with Non-Acetaminophen-Induced Acute Liver Failure." Liver Transpl 14.1 (2008): 25-30.
  93. Beloqui O, Prieto J, Suárez M, et al. N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis C: a pilot study. J Interferon Res. 1993 Aug;13(4):279-82.
  94. Grant PR, Black A, Garcia N, et al. Combination therapy with interferon-alpha plus N-acetyl cysteine for chronic hepatitis C: a placebo controlled double-blind multicentre study. J Med Virol. 2000 Aug;61(4):439-42.
  95. Gunduz H, Karabay O, Tamer A, et al. N-acetyl cysteine therapy in acute viral hepatitis. World J Gastroenterol. 2003 Dec;9(12):2698-700.
  96. Nahas R, Sheikh O. "Complementary and Alternative Medicine for the Treatment of Major Depressive Disorder." Can Fam Physician 57.6 (2011): 659-63. http://www.ncbi.nlm.nih.gov/pubmed/21673208
  97. Medici V, Virata MC, Peerson JM, et al. "S-Adenosyl-L-Methionine Treatment for Alcoholic Liver Disease: A Double-Blinded, Randomized, Placebo-Controlled Trial." Alcohol ClinExp Res 35.11 (2011): 1960-5.
  98. Feld JJ, Modi AA, El-Diwany R, et al. "S-Adenosyl Methionine Improves Early Viral Responses and Interferon-Stimulated Gene Induction in Hepatitis C Nonresponders." Gastroenterology 140.3 (2011): 830-9. http://www.ncbi.nlm.nih.gov/pubmed/20854821
  99. Filipowicz M, Bernsmeier C, Terracciano L, et al. S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponse. PLoS One. 2010 Nov 8;5(11):e15492.
  100. Shay KP, Moreau RF, Smith EJ, et al. “Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential.” BiochimBiophysActa 1790.10 (2009): 1149-60.
  101. Park KG, Min AK, Koh EH, et al. "Alpha-Lipoic Acid Decreases Hepatic Lipogenesis through Adenosine Monophosphate-Activated Protein Kinase (AMPK)-Dependent and AMPK-Independent Pathways." Hepatology 48.5 (2008):1477-86. http://www.ncbi.nlm.nih.gov/pubmed/18972440
  102. Melhem A, Stern M, Shibolet O, et al. "Treatment of Chronic Hepatitis C Virus Infection via Antioxidants: Results of a Phase I Clinical Trial." J ClinGastroenterol 39.8 (2005): 737-42.
  103. Berkson BM. A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories. Med Klin (Munich). 1999 Oct 15;94 Suppl 3:84-9.
  104. El-Attar GM, Saleh ZA, El-Shibiny SS. "The Use of Whey Protein Concentrate in Management of Chronic Hepatitis C: A Pilot Study." Aust. J. Basic Appl. Sci. 3.2 (2009): 1060-1069.
  105. Kume H, Okazaki K, and Sasaki H. Hepatoprotective effects of whey protein on D-galactosamine-induced hepatitis and liver fibrosis in rats. BiosciBiotechnolBiochem. 2006 May;70(5):1281-5.
  106. Khan MS, Dilawar S, Ali I, et al. "The Possible Role of Selenium Concentration in Hepatitis B and C Patients." Saudi J Gastroenterol 18.2 (2012): 106-10. http://www.ncbi.nlm.nih.gov/pubmed/22421715
  107. Rohr-Udilova N, Sieghart W, Eferl R, et al. "Antagonistic Effects of Selenium and Lipid Peroxides on Growth Control in Early Hepatocellular Carcinoma." Hepatology. 2012 Apr;55(4):1112-21.
  108. Himoto T, Yoneyama H, Kurokohchi K, et al. "Selenium Deficiency Is Associated with Insulin Resistance in Patients with Hepatitis C Virus-Related Chronic Liver Disease." Nutr Res 31.11 (2011): 829-35.
  109. Jones DP, Hagen TM, Weber R, et al. Oral administration of glutathione (GSH) increases plasma GSH concentrations in humans, FASEB J., 3 (1989) A1250.
  110. Hagen TM, Wierzbicka GT, Sillau AH, et al. Bioavailability of dietary glutathione: effect on plasma concentration. Am J Physiol. 1990 Oct;259(4 Pt 1):G524-9.
  111. Kariya C, Leitner H, Min E, et al. A role for CFTR in the elevation of glutathione levels in the lung by oral glutathione administration. Am J Physiol Lung Cell Mol Physiol. 2007 Jun;292(6):L1590-7.
  112. Aw TY, Wierzbicka G, and Jones DP. Oral glutathione increases tissue glutathione in vivo. ChemBiol Interact. 1991;80(1):89-97.
  113. Iantomasi T, Favilli F, Marraccini P, et al. thione transport system in human small intestine epithelial cells. BiochimBiophysActa. 1997 Dec 4;1330(2):274-83.
  114. Favilli F, Marraccini P, Iantomasi T, et al. Effect of orally administered glutathione on glutathione levels in some organs of rats: role of specific transporters. Br J Nutr. 1997 Aug;78(2):293-300.
  115. Actor JK, Hwang SA, Kruzel ML. "Lactoferrin as a Natural Immune Modulator." Curr Pharm Des 17 (2009): 1956-73. http://www.ncbi.nlm.nih.gov/pubmed/19519436
  116. Ishii K, Takamura N, Shinohara M, et al. "Long-Term Follow-Up of Chronic Hepatitis C Patients Treated with Oral Lactoferrin for 12 Months." Hepatol Res 25.3 (2003): 226-233.
  117. Kaito M, Iwasa M, Fujita N, et al. "Effect of Lactoferrin in Patients with Chronic Hepatitis C: Combination Therapy with Interferon and Ribavirin." J GastroenterolHepatol 22.11 (2007): 1894-7.
  118. Ciesek S, von Hahn T, Colpitts CC, et al. "The Green Tea Polyphenol, Epigallocatechin-3-Gallate, Inhibits Hepatitis C Virus Entry." Hepatology 54.6 (2011): 1947-55.
  119. Ma Q, Kim EY, Lindsay EA, et al. “Bioactive dietary polyphenols inhibit heme iron absorption in a dose-dependent manner in human intestinal caco-2 cells.” J Food Sci. 2011 Jun;76(5):H143-50.
  120. Saewong T, Ounjaijean S, Mundee Y, et al. “Effects of green tea on iron accumulation and oxidative stress in livers of iron-challenged thalassemic mice.” Med Chem. 2010 Mar;6(2):57-64.
  121. Shawki A, Mackenzie B. "Interaction of Calcium with the Human Divalent Metal-Ion Transporter-1." BiochemBiophys Res Commun 393.3 (2010): 471-5.
  122. Hallberg L, Brune M, Erlandsson M, et al. "Calcium: Effect of Different Amounts On Nonheme- And Heme-Iron Absorption in Humans." Am J ClinNutr 53.1 (1991): 112-9.
  123. Polyak SJ, Morishima C, Shuhart MC, et al. "Inhibition of T-Cell Inflammatory Cytokines, Hepatocyte NF-Kappab Signaling, and HCV Infection by Standardized Silymarin." Gastroenterology 132.5 (2007): 1925-36. http://www.ncbi.nlm.nih.gov/pubmed/17484885
  124. Bonifaz V, Shan Y, Lambrecht RW, et al. "Effects of Silymarin on Hepatitis C Virus and Haem Oxygenase-1 Gene Expression in Human Hepatoma Cells." Liver Int 29.3 (2009): 366-73.
  125. Morishima C, Shuhart MC, Wang CC, et al. "Silymarin Inhibits in Vitro T-Cell Proliferation and Cytokine Production in Hepatitis C Virus Infection." Gastroenterology 138.2 (2010): 671-81, 681.e1-2.
  126. El-Lakkany NM, Hammam OA, El-Maadawy WH, et al. “Anti-inflammatory/anti-fibrotic effects of the hepatoprotectivesilymarin and the schistosomicidepraziquantel against Schistosomamansoni-induced liver fibrosis.” Parasit Vectors. 11.5 (2012): 9. http://www.ncbi.nlm.nih.gov/pubmed/22236605
  127. Mayer KE, Myers RP, Lee SS. "Silymarin Treatment of Viral Hepatitis: A Systematic Review." J Viral Hepat 12.6 (2005): 559-67. http://www.ncbi.nlm.nih.gov/pubmed/16255756
  128. Wagoner J, Negash A, Kane OJ, et al. "Multiple Effects of Silymarin on the Hepatitis C Virus Lifecycle." Hepatology 51.6 (2010): 1912-21. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2909978/?tool=pubmed
  129. Seeff LB, Curto TM, Szabo G, et al. "Herbal Product Use by Persons Enrolled in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial." Hepatology 47.2 (2008): 605-12.
  130. Hawke RL, Schrieber SJ, Soule TA, et al. "Silymarin Ascending Multiple Oral Dosing Phase I Study in Noncirrhotic Patients with Chronic Hepatitis C." J ClinPharmacol 50.4 (2010): 434-49.
  131. Loguercio C, Festi D. "Silybin and the Liver: From Basic Research to Clinical Practice." World J Gastroenterol 17.18 (2011): 2288-301.
  132. Trappoliere M, Caligiuri A, Schmid M, et al. "Silybin, A Component of Sylimarin, Exerts Anti-Inflammatory and Anti-Fibrogenic Effects on Human Hepatic Stellate Cells." J Hepatol 50.6 (2009): 1102-11.
  133. Ahmed-Belkacem A, Ahnou N, Barbotte L, et al. "Silibinin and Related Compounds Are Direct Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase." Gastroenterology 138.3 (2010): 1112-22.
  134. Ferenci P, Scherzer TM, Kerschner H, et al. "Silibinin Is a Potent Antiviral Agent in Patients with Chronic Hepatitis C Not Responding to Pegylated Interferon/Ribavirin Therapy." Gastroenterology 135.5 (2008): 1561-7. http://www.ncbi.nlm.nih.gov/pubmed/18771667
  135. Verma S, Thuluvath PJ. "Complementary and Alternative Medicine in Hepatology: Review of the Evidence of Efficacy." ClinGastroenterolHepatol 5.4 (2007): 408-16.
  136. Eurich D, Bahra M, Berg T, et al. Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy. ExpClin Transplant. 2011 Feb;9(1):1-6.
  137. Rutter K, Scherzer TM, Beinhardt S, et al. Intravenous silibinin as 'rescue treatment' for on-treatment non-responders to pegylated interferon/ribavirin combination therapy. AntivirTher. 2011;16(8):1327-33.
  138. Neumann UP, Biermer M, Eurich D, et al. "Successful Prevention of Hepatitis C Virus (HCV) Liver Graft Reinfection by Silibinin Mono-Therapy." J Hepatol 52.6 (2010): 951-2.
  139. Okiyama W, Tanaka N, Nakajima T, et al. "Polyenephosphatidylcholine Prevents Alcoholic Liver Disease in PPARalpha-Null Mice through Attenuation of Increases in Oxidative Stress." JHepatol 50.6 (2009): 1236-46. http://www.ncbi.nlm.nih.gov/pubmed/19398233
  140. Singal AK, Jampana SC, Weinman SA. "Antioxidants as Therapeutic Agents for Liver Disease." Liver Int 31.10 (2011): 1432-48. http://onlinelibrary.wiley.com/doi/10.1111/j.1478-3231.2011.02604.x/full
  141. Lieber CS. "Pathogenesis and Treatment of Alcoholic Liver Disease: Progress over the Last 50 Years." RoczAkad Med Bialymst 50 (2005):7-20. http://www.ncbi.nlm.nih.gov/pubmed/16363067
  142. Zhao QY, Wang HY, Zhang WX, et al. "[Protective Effect of Polyenylphosphatidyl Choline on Liver in Rat with Sepsis]." Zhongguo Wei Zhong Bing JiJiu Yi Xue 23.7 (2011): 401-4.
  143. Gundermann KJ, Kuenker A, Kuntz E, et al. Activity of essential phospholipids (EPL) from soybean in liver diseases. Pharmacol Rep. 2011;63(3):643-59.
  144. Azzam HS, Goertz C, Fritts M, et al. "Natural Products and Chronic Hepatitis C Virus." Liver Int 27.1 (2007): 17-25. http://www.ncbi.nlm.nih.gov/pubmed/17241377
  145. Chien CF, Wu YT, Tsai TH. “Biological Analysis of Herbal Medicines Used for the Treatment of Liver Diseases.” Biomed Chromatogr 25.1-2 (2011):21-38.
  146. Cyong JC, Ki SM, Iijima K, Kobayashi T, et al. "Clinical and pharmacological studies on liver diseases treated with Kampo herbal medicine." Am J Chin Med 28.3-4 (2000): 351-60.
  147. Wang R, Kong J, Wang D, et al. "A Survey of Chinese Herbal Ingredients with Liver Protection Activities." Chin Med10.2 (2007): 5. http://www.ncbi.nlm.nih.gov/pubmed/17490493
  148. Ashfaq UA, Masoud MS, Nawaz Z, et al. "Glycyrrhizin as Antiviral Agent against Hepatitis C Virus." J Transl Med 9 (2011): 112. http://www.biomedcentral.com/content/pdf/1479-5876-9-112.pdf
  149. Guyton KZ, Kensler TW. "Prevention of Liver Cancer." CurrOncol Rep. 4.6 (2002): 464-70.
  150. Kumada H. "Long-Term Treatment of Chronic Hepatitis C with Glycyrrhizin [Stronger Neo-Minophagen C (SNMC)] for Preventing Liver Cirrhosis and Hepatocellular Carcinoma." Oncology 62 Suppl 1 (2002): 94-100. http://www.ncbi.nlm.nih.gov/pubmed/11868794
  151. Schröfelbauer B, Raffetseder J, Hauner M, et al. "Glycyrrhizin, the Main Active Compound in Liquorice, Attenuates Pro-Inflammatory Responses by Interfering with Membrane-Dependent Receptor Signalling." Biochem J 421.3 (2009): 473-82. http://www.biochemj.org/bj/421/0473/bj4210473.htm
  152. Li XL, Zhou AG, Zhang L, et al. "Antioxidant Status and Immune Activity of Glycyrrhizin in Allergic Rhinitis Mice." Int J MolSci 12.2 (2011): 905-16. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083680/
  153. Gomez EV, Perez YM, Sanchez HV, et al. "Antioxidant and Immunomodulatory Effects of Viusid in Patients with Chronic Hepatitis C." World J Gastroenterol 16.21 (2010): 2638-47.
  154. Vilar Gomez E, Gra Oramas B, Soler E, et al. Viusid, a nutritional supplement, in combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Liver Int. 27.2 (2007): 247-59.
  155. Korenaga M, Hidaka I, Nishina S, et al. "A Glycyrrhizin-Containing Preparation Reduces Hepatic Steatosis Induced by Hepatitis C Virus Protein and Iron in Mice." Liver Int 31.4 (2011): 552-60.
  156. Hidaka I, Hino K, Korenaga M, et al. "Stronger Neo-Minophagen C, A Glycyrrhizin-Containing Preparation, Protects Liver against Carbon Tetrachloride-Induced Oxidative Stress in Transgenic Mice Expressing the Hepatitis C Virus Polyprotein." Liver Int 27.6 (2007): 845-53.
  157. Nielsen ML, Pareek M, Andersen I. "[Liquorice-Induced Hypertension and Hypokalaemia.]" UgeskrLaeger 174.15 (2012): 1024-1025. http://www.ncbi.nlm.nih.gov/pubmed/22487411
  158. Arteh J, Narra S, Nair S. "Prevalence of vitamin D deficiency in chronic liver disease." Dig Dis Sci 55.9 (2010): 2624-8. http://www.ncbi.nlm.nih.gov/pubmed/19960254
  159. Petta S, Cammà C, Scazzone C, et al. "Low Vitamin D Serum Level Is Related to Severe Fibrosis and Low Responsiveness to Interferon-Based Therapy in Genotype 1 Chronic Hepatitis C." Hepatology 51.4 (2010): 1158-67. http://onlinelibrary.wiley.com/doi/10.1002/hep.23489/full
  160. Abu-Mouch S, Fireman Z, Jarchovsky J, et al. "Vitamin D Supplementation Improves Sustained Virologic Response in Chronic Hepatitis C (Genotype 1)-Naïve Patients." World J Gastroenterol 17.47 (2011): 5184-90. http://www.ncbi.nlm.nih.gov/pubmed/22215943
  161. Nimer A, Mouch A. "Vitamin D Improves Viral Response in Hepatitis C Genotype 2-3 Naïve Patients." World J Gastroenterol 18.8 (2012): 800-5. http://www.wjgnet.com/1007-9327/pdf/v18/i8/800.pdf
  162. Freedman ND, Curto TM, Lindsay KL, et al. "Coffee Consumption Is Associated With Response to Peginterferon and Ribavirin Therapy in Patients with Chronic Hepatitis C." Gastroenterology 140.7 (2011): 1961-9.
  163. Modi AA, Feld JJ, Park Y, et al. "Increased Caffeine Consumption Is Associated with Reduced Hepatic Fibrosis." Hepatology 51.1 (2010): 201-9. http://www.ncbi.nlm.nih.gov/pubmed/20034049
  164. Klatsky AL, Morton C, Udaltsova N, et al. "Coffee, Cirrhosis, and Transaminase Enzymes." Arch Intern Med 166.11 (2006): 1190-5. http://www.ncbi.nlm.nih.gov/pubmed/16772246
  165. Larsson SC, Wolk A. "Coffee Consumption and Risk of Liver Cancer: A Meta-Analysis." Gastroenterology 132.5 (2007): 1740-5. http://www.ncbi.nlm.nih.gov/pubmed/17484871
  166. Bravi F, Bosetti C, Tavani A, et al. "Coffee Drinking and Hepatocellular Carcinoma Risk: A Meta-Analysis." Hepatology 46.2 (2007): 430-5. http://www.ncbi.nlm.nih.gov/pubmed/17580359
  167. Freedman ND, Everhart JE, Lindsay KL, et al. "Coffee Intake Is Associated with Lower Rates of Liver Disease Progression in Chronic Hepatitis C." Hepatology 50.5 (2009): 1360-9.
  168. Ruhl CE, Everhart JE. "Coffee And Caffeine Consumption Reduce the Risk of Elevated Serum Alanine Aminotransferase Activity in the United States." Gastroenterology 128.1 (2005a): 24-32. http://www.ncbi.nlm.nih.gov/pubmed/15633120
  169. Ruhl CE, Everhart JE. "Coffee and Tea Consumption Are Associated with a Lower Incidence of Chronic Liver Disease in the United States." Gastroenterology 129.6 (2005b): 1928-36.
  170. Wang GF, Shi LP, Ren YD, et al. Anti-hepatitis B virus activity of chlorogenic acid, quinic acid and caffeic acid in vivo and in vitro. Antiviral Res. 2009 Aug;83(2):186-90.
  171. Yuasa K, Naganuma A, Sato K, et al. "Zinc Is a Negative Regulator of Hepatitis C Virus RNA Replication." Liver Int 26.9 (2006): 1111-8. http://onlinelibrary.wiley.com/doi/10.1111/j.1478-3231.2006.01352.x/abstract
  172. Takagi H, Nagamine T, Abe T, et al. "Zinc Supplementation Enhances the Response to Interferon Therapy in Patients with Chronic Hepatitis C." J Viral Hepat 8.5 (2001): 367-71.
  173. Ko WS, Guo CH, Hsu GS, et al. "The Effect of Zinc Supplementation on the Treatment of Chronic Hepatitis C Patients with Interferon and Ribavirin." ClinBiochem 38.7 (2005b): 614-20.
  174. Murakami Y, Koyabu T, Kawashima A, et al. "Zinc Supplementation Prevents the Increase of Transaminase in Chronic Hepatitis C Patients during Combination Therapy with Pegylated Interferon Alpha-2b and Ribavirin." J NutrSciVitaminol (Tokyo) 53.3 (2007): 213-8.
  175. Matsuoka S, Matsumura H, Nakamura H, et al. "Zinc Supplementation Improves the Outcome of Chronic Hepatitis C and Liver Cirrhosis." J ClinBiochemNutr 45.3 (2009): 292-303.
  176. Himoto T, Hosomi N, Nakai S, et al. "Efficacy of Zinc Administration in Patients with Hepatitis C Virus-Related Chronic Liver Disease." Scand J Gastroenterol 42.9 (2007): 1078-87.
  177. Suzuki H, Takagi H, Sohara N, et al. "Triple Therapy of Interferon and Ribavirin with Zinc Supplementation for Patients with Chronic Hepatitis C: A Randomized Controlled Clinical Trial." World J Gastroenterol 12.8 (2006): 1265-9. http://www.ncbi.nlm.nih.gov/pubmed/16534882
  178. Aggarwal BB, Kumar A, Bharti AC. "Anticancer Potential of Curcumin: Preclinical and Clinical Studies." Anticancer Res 23.1A (2003): 363-98. http://www.ncbi.nlm.nih.gov/pubmed/12680238
  179. Rahman I, Biswas SK, Kirkham PA. "Regulation of Inflammation and Redox Signaling by Dietary Polyphenols." BiochemPharmacol. 72.11 (2006): 1439-52.
  180. Aggarwal BB, Sundaram C, Malani N, et al. "Curcumin: the Indian Solid Gold." AdvExp Med Biol 595 (2007): 1-75. http://www.ncbi.nlm.nih.gov/pubmed/17569205
  181. Li CJ, Zhang LJ, Dezube BJ, et al. "Three Inhibitors of Type 1 Human Immunodeficiency Virus Long Terminal Repeat-Directed Gene Expression and Virus Replication." PNAS 90.5 (1993): 1839-1842.
  182. Chen D, Shien J, Tiley L, et al. "Curcumin Inhibits Influenza Virus Infection and Haemagglutination Activity." Food Chem 119.4 (2010): 1346-1351.
  183. Si X, Wang Y, Wong J, et al. "Dysregulation of the Ubiquitin-Proteasome System by Curcumin Suppresses Coxsackievirus B3 Replication." J Virol 81.7 (2007): 3142-50.
  184. Kim K, Kim KH, Kim HY, et al. "Curcumin Inhibits Hepatitis C Virus Replication via Suppressing the Akt-SREBP-1 Pathway." FEBS Lett 584.4 (2010): 707-12. http://www.ncbi.nlm.nih.gov/pubmed/20026048
  185. Darvesh AS, Aggarwal BB, Bishayee A, et al. Curcumin and liver cancer: a review. Curr Pharm Biotechnol. 2012 Jan;13(1):218-28.
  186. Boots AW, Haenen GR, Bast A. "Health Effects of Quercetin: from Antioxidant to Nutraceutical." Eur J Pharmacol 585.2-3 (2008): 325-37. http://www.ncbi.nlm.nih.gov/pubmed/18417116
  187. Gonzalez O, Fontanes V, Raychaudhuri S, et al. "The Heat Shock Protein Inhibitor Quercetin Attenuates Hepatitis C Virus Production." Hepatology 50.6 (2009): 1756-64. http://www.ncbi.nlm.nih.gov/pubmed/19839005
  188. Bachmetov L, Gal-Tanamy M, Shapira A, et al. Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity. J Viral Hepat. 2012 Feb;19(2):e81-8.
  189. Malaguarnera M, Vacante M, Giordano M, et al. "L-Carnitine Supplementation Improves Hematological Pattern in Patients Affected by HCV Treated with Peg Interferon-α 2b Plus Ribavirin." World J Gastroenterol 17.39 (2011a): 4414-20. http://www.ncbi.nlm.nih.gov/pubmed/22110268
  190. Malaguarnera M, Vacante M, Bertino G, et al. "The Supplementation of Acetyl-L-Carnitine Decreases Fatigue and Increases Quality of Life in Patients with Hepatitis C Treated with Pegylated Interferon-α 2b Plus Ribavirin." J Interferon Cytokine Res 31.9 (2011b): 653-9. http://www.ncbi.nlm.nih.gov/pubmed/21923249